ArticleFrontiers in immunology2026
Integrated metabolomic and cytokine profiling reveals biomarkers across the clinical spectrum of lupus nephritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lupus nephritis (LN) represents one of the most frequent and severe manifestations of systemic lupus erythematosus (SLE), highlighting an urgent need for novel non-invasive approaches to improve its diagnosis and clinical monitoring. Objectives: To characterize serum and urinary metabolomic profiles, together with urinary cytokine expression, in patients with lupus nephritis (LN) across the clinical spectrum from active disease, post-induction response, and sustained remission. Methods: We enrolled 62 patients fulfilling the 2019 ACR/EULAR SLE criteria, divided into three groups: active LN (n=21), post-induction responders at 6 months (n=21), and sustained responders with ≥2 years of remission (n=20). Untargeted metabolomic profiling of serum and urine was performed using GC-MS, and urinary cytokines were measured by luminometry. Statistical analyses included Kruskal-Wallis tests and multinomial logistic regression. Results: Median age was 36 years; 87% were female. Twelve serum metabolites and ten urinary metabolites differed significantly across groups. Active LN patients showed increased urinary threonate and elevated cytokines (15 out of 17 measured, including IL-10). Serum glycerol was significantly higher in post-induction responders compared to sustained responders, while urinary sucrose was lower in this group. Logistic regression identified urinary threonate as discriminative for active LN, whereas serum glycerol (OR 1.05, 95% CI 1.048-1.050) and urinary sucrose (OR 0.98, 95% CI 0.9802-0.981) differentiated post-induction from sustained response. Increased urinary IL-10 was strongly associated with active LN, while G-CSF discriminated post-induction from sustained responders. Discussion and conclusions: The combined analysis of serum/urinary metabolomic profiles and urinary cytokines provides discriminatory power to differentiate active LN from remission states, supporting their potential role as non-invasive biomarkers for diagnosis and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.